Terguride is currently being evaluated for pulmonary arterial hypertension (PAH) in a pivotal Phase II trial in Europe.
Rudolf Reiter, CEO of Ergonex Pharma, said: “The FDA’s grant of orphan drug designation to Terguride for PAH encourages and strengthens our development program by offering regulatory, clinical development and commercial benefits. We believe that Terguride can provide a significant therapeutic benefit in PAH by inhibiting excess serotonin signalling.”